Engagement of Cellular Mitotic and Antiviral Signaling by Poxviral Kinases

Information

  • Research Project
  • 10458234
  • ApplicationId
    10458234
  • Core Project Number
    R56AI153099
  • Full Project Number
    1R56AI153099-01A1
  • Serial Number
    153099
  • FOA Number
    PA-20-185
  • Sub Project Id
  • Project Start Date
    8/12/2021 - 3 years ago
  • Project End Date
    7/31/2022 - 2 years ago
  • Program Officer Name
    GAUTAM, RAJEEV
  • Budget Start Date
    8/12/2021 - 3 years ago
  • Budget End Date
    7/31/2022 - 2 years ago
  • Fiscal Year
    2021
  • Support Year
    01
  • Suffix
    A1
  • Award Notice Date
    8/12/2021 - 3 years ago

Engagement of Cellular Mitotic and Antiviral Signaling by Poxviral Kinases

Viral manipulation of mitotic and antiviral signal transduction determines the outcome of infection but remains poorly understood. To address this knowledge gap, our laboratory studies a family of protein kinases comprised of homologs widely expressed in poxviruses and in all multicellular eukaryotes. The long term goal of our research is to determine how poxviruses usurp and redirect signaling cascades governing mitotic and host defense effectors responsive to foreign DNA. Mammalian poxviruses express two proteins, B1 and B12, which are homologous to each other and to three eukaryotic protein kinases named vaccinia related kinases (VRKs). Comparative studies of B1 and VRK1 revealed that both enzymes directly modify the cellular protein BAF. Importantly, BAF acts as both a mitotic regulator and antiviral effector by binding and compacting dsDNA, a property that is inactivated via phosphorylation by B1 or VRK1. Our new data argue that B1 and cellular VRKs co-regulate other pathways as well, including an antiviral pathway activated by the B12 protein. Our data indicate that B12 directs strong repression of vaccinia DNA replication via an unknown mechanism governed by B1. Intriguingly, B12 is a nuclear poxviral protein and a non-catalytic kinase or ?pseudokinase?, which are of key innovative importance for this proposal. Pseudokinases are members of the pseudoenzyme family, about which little is known in viruses. It is our central hypothesis that vaccinia B1 and B12 form a novel signaling axis that supplants and redirects cellular VRK pathways regulating BAF and other VRK substrates such as histones. To test our hypothesis, we propose three aims. AIM 1) Determine how B1 and B12 remodel VRK1- responsive BAF and histone H2A signaling during poxvirus infection. This Aim tests the hypothesis that B12 interacts with VRKs in the nucleus, thereby altering H2A and BAF phosphorylation, and augmenting BAF:DNA interaction throughout the cell. Characterization of B12 interaction with BAF, B1, and cellular VRKs in vitro and in cultured cells will be achieved. AIM 2) Determine the molecular mechanisms governing B12 repression of poxvirus DNA replication. This Aim tests the hypothesis that B12 possesses ATP binding and other functional elements of active kinases that play key roles in how B12 dysregulates signaling. Structure/function analysis of B12 through targeted mutational analysis, novel loss of function screens, and investigation of B12 phosphoregulation are outlined in this Aim. AIM 3) Determine how viral/cellular pseudokinases mediate repression of the poxvirus lifecycle and converge with protein phosphatase signaling. This Aim will test the hypotheses that B1 and VRK2 kinases regulate B12 via direct phosphorylation while VRK3 and the phosphatase PP2A control dynamic regulation of B1/VRK1 substrates, leading to manipulation of downstream antiviral responses. The completion of this work will: fill gaps in our understanding of poxvirus manipulation of nuclear processes, yield broadly relevant insights to the field of kinase-pseudokinase biology, and provide needed information of how mitotic and antiviral signaling interweave.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R56
  • Administering IC
    AI
  • Application Type
    1
  • Direct Cost Amount
    277355
  • Indirect Cost Amount
    148423
  • Total Cost
    425778
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    855
  • Ed Inst. Type
  • Funding ICs
    NIAID:425778\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    VIRA
  • Study Section Name
    Virology - A Study Section
  • Organization Name
    UNIVERSITY OF NEBRASKA LINCOLN
  • Organization Department
  • Organization DUNS
    555456995
  • Organization City
    LINCOLN
  • Organization State
    NE
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    685032427
  • Organization District
    UNITED STATES